NBRV - Nabriva Therapeutics GAAP EPS of -$0.20 misses by $0.01 revenue of $8.02M misses by $1.55M May, 05 2022 04:33 PM Nabriva Therapeutics plc Nabriva Therapeutics press release (NASDAQ:NBRV): Q1 GAAP EPS of -$0.20 misses by $0.01. Revenue of $8.02M (+218.3% Y/Y) misses by $1.55M. For further details see: Nabriva Therapeutics GAAP EPS of -$0.20 misses by $0.01, revenue of $8.02M misses by $1.55M